Manufacturing Chemist Manufacturing Chemist
  • Home
  • Ingredients
  • Analysis
  • Manufacturing
  • Finance
  • Events
  • Directory
  • Regulatory
  • Drug Delivery
  • Research & Development
  • Sustainability

Bristol-Myers Squibb

www.bms.com

345 Park Avenue
New York
New York
10154
United States

+1 212 546 4000

Activities

Pharmaceutical

Related Content

Therapeutic: mavacamten for hypertrophic cardiomyopathy
Therapeutic: mavacamten for hypertrophic cardiomyopathy
Anteros enters the market powered by BioMotiv and Bristol-Myers Squibb
Anteros enters the market powered by BioMotiv and Bristol-Myers Squibb
Bristol-Myers Squibb and Catalent close Italian manufacturing deal
Bristol-Myers Squibb and Catalent close Italian manufacturing deal
Bristol-Myers Squibb invests in drug development accelerator BioMotiv
Bristol-Myers Squibb invests in drug development accelerator BioMotiv
Catalent to acquire Bristol-Myers Squibb manufacturing plant in Italy
Catalent to acquire Bristol-Myers Squibb manufacturing plant in Italy
Biocartis and BMS to collaborate on MSI testing with immuno-oncology therapies
Biocartis and BMS to collaborate on MSI testing with immuno-oncology therapies
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
Bristol-Myers Squibb to merge with Celgene in multimillion deal
Bristol-Myers Squibb to merge with Celgene in multimillion deal
Eisai, BMS and H3 Biomedicine announce research collaboration
Eisai, BMS and H3 Biomedicine announce research collaboration
BMS and Vedanta announce a new clinical collaboration to evaluate OPDIVO (nivolumab) and VE800
BMS and Vedanta announce a new clinical collaboration to evaluate OPDIVO (nivolumab) and VE800
GlobalData publishes analysis of top 25 global pharma companies
GlobalData publishes analysis of top 25 global pharma companies
GlobalData names top 25 global pharma companies by market cap
GlobalData names top 25 global pharma companies by market cap
Melanoma sales projected to rise to $5.5 bn in 2026
Melanoma sales projected to rise to $5.5 bn in 2026
CTA for armed oncolytic virus treatment of solid tumours
CTA for armed oncolytic virus treatment of solid tumours
Efficient handling of DNA samples with automatic capping solution
Efficient handling of DNA samples with automatic capping solution
  • Advertise Subscribe
  • Terms & Conditions
  • Privacy Policy
  • Contact us at info@hpcimedia.com
Twitter LinkedIn RSS newsfeed
© HPCi Media Limited | Registered in England No. 6716035 | VAT GB 939828072 | a Claverley Group company